What question did this study set out to answer?

To adapt the Impact-R cone and platelet analyzer to evaluate agonist-induced platelet aggregation alongside platelet adhesion.

January 1, 2008Platelets

Testing agonist-induced platelet aggregation by the Impact-R Cone and plate(let) analyzer (CPA)

Q: What is the clinical evidence from this study?

Study design: Other. Population: Platelet aggregation defects (n=10). Intervention: Impact-R agonist-response test vs. Impact-R regular test and Light transmission platelet aggregometry (LTA). Primary outcome: Platelet adhesion (surface coverage, SC).

View Full Paper

Ask AI

Bookmark

Key result

The Impact-R agonist-response test successfully measured agonist-induced platelet aggregation, showing reduced surface coverage (1.2% to 2.4%) compared to the regular test (11.2%) in healthy volunteers.

Why the study?

Does the Impact-R agonist-response test accurately assess agonist-induced platelet aggregation compared to standard LTA?

Population

Blood samples from 10 healthy volunteers and patients with storage pool disease, severe von Willebrand…

Comparison

Impact-R agonist-response test vs Light transmission platelet aggregometry and…

Design

Preclinical

Authors

БШБ. С. ШенкманInstitute of Biomedical Problems YEYulia EinavHolon Institute of Technology OSOphira SalomonTel Aviv University

Discussion

Member takes

Implication

Supports Impact-R for agonist testing in volunteers; leaves open accuracy versus LTA and clinical adoption.

Key Points

To adapt the Impact-R cone and platelet analyzer to evaluate agonist-induced platelet aggregation alongside platelet adhesion.
Tested whole blood samples from 10 healthy volunteers using light transmission platelet aggregometry (LTA), standard Impact-R tests, and an Impact-R agonist-response test.
Pre-incubated blood for 1 minute with agonists (ADP, ristocetin, epinephrine, collagen, arachidonic acid) to induce micro-aggregate formation and quantified surface coverage (SC) under shear stress.
Evaluated assay sensitivity using prostaglandin E1, the P2Y12 receptor inhibitor 2MeSAMP, and clinical blood samples from patients with known platelet defects.
Baseline Impact-R surface coverage in healthy volunteers was 11.2 ± 2.6%, which decreased to 1.2 ± 0.9% to 2.4 ± 0.4% across agonists in the agonist-response test, mirroring high maximal LTA aggregation (81% to 93%).
Prostaglandin E1 reduced agonist-induced SC decline (SC of 8.8 ± 1.8% for ADP and 9.5 ± 2.0% for epinephrine), while 2MeSAMP caused a dose-dependent decrease in ADP-induced aggregation that inversely correlated with Impact-R SC.
The agonist-response assay successfully identified aggregation deficiencies in patients diagnosed with storage pool disease, severe von Willebrand disease, and epinephrine response deficiency.

Structured PICO

Does the Impact-R agonist-response test accurately assess agonist-induced platelet aggregation compared to standard LTA?

Population

10 healthy volunteers and an unspecified number of patients with specific platelet defects evaluated using the Impact-R agonist-response test.

Exposure

Impact-R agonist-response test (pre-incubation with agonist for 1 min)

Comparator

Light transmission platelet aggregometry (LTA) and Impact-R regular test

Outcome

Platelet adhesion (surface coverage, SC) and maximal aggregationsurrogate

The Impact-R agonist-response test is a viable method to detect aggregation defects and assess the effect of different agonists on platelet aggregation.

Cite This Study

Шенкман et al. (2008) studied Platelet aggregation defects (n=10). Impact-R agonist-response test vs. Impact-R regular test and Light transmission platelet aggregometry (LTA) was evaluated on Platelet adhesion (surface coverage, SC). The Impact-R agonist-response test successfully measured agonist-induced platelet aggregation, showing reduced surface coverage (1.2% to 2.4%) compared to the regular test (11.2%) in healthy volunteers.

synapsesocial.com/papers/6a8476aedc9bcdcbf8c6c71b https://doi.org/10.1080/09537100802082256

View Full Paper

Ask AI

Bookmark

Testing agonist-induced platelet aggregation by the Impact-R Cone and plate(let) analyzer (CPA)

Discussion

Member takes

Implication

Key Points

Structured PICO

Cite This Study

Testing agonist-induced platelet aggregation by the Impact-R Cone and plate(let) analyzer (CPA)

Discussion

Member takes

Implication

Key Points

Structured PICO

Cite This Study

Also Consider

Also Consider